ストックスクリーナーアプリを入手
22.71
3.53%
-0.83
アフターアワーズ：
22.55
-0.16
-0.70%
Tandem Diabetes Care Inc (TNDM) 最新ニュース
Will Tandem Diabetes Care Inc. stock benefit from infrastructure spendingFlag and Pennant Patterns & Low Cost Capital Trading - ulpravda.ru
Positive changes ahead for diabetes in 2026 - BioWorld MedTech
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - The Globe and Mail
Disposable Insulin Pumps Market is expected to reach US$ 6.9 - openPR.com
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - PR Newswire
Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules - TipRanks
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Favourable Signals For Tandem Diabetes Care: Numerous Insiders Acquired Stock - 富途牛牛
ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE - GlobeNewswire Inc.
HEDIS Glycemic Goal Achieved Using Control-IQ Technology - The American Journal of Managed Care® (AJMC®)
Is Tandem Diabetes Care (TNDM) Still Undervalued After Its Recent Share Price Rebound? - Yahoo Finance
What Tandem Diabetes Care (TNDM)'s Canadian Smartphone Bolus Launch Means For Shareholders - Yahoo Finance
Tandem Diabetes Care (FRA:TD5A) EV-to-OCF : -179.84 (As of Dec. 25, 2025) - GuruFocus
Should Tandem’s Canadian Smartphone Bolus Launch Reshape How Investors View TNDM’s Connected-Care Strategy? - Sahm
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Artificial Pancreas System Market is set for steady growth to US$ - openPR.com
Price-Driven Insight from (TNDM) for Rule-Based Strategy - news.stocktradersdaily.com
Clinical ink announces collaboration with Tandem Diabetes Care to integrate Automated Insulin Delivery data into the GlucoseReady™ connected device software platform - PRWeb
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
Gainers Report: Why Tandem Diabetes Care Inc. (TD5A) stock could break out in 2025Trade Risk Assessment & Verified Momentum Stock Watchlist - Улправда
Why Tandem Diabetes Care Inc. (TD5A) stock is a strong analyst pickQuarterly Trade Review & AI Enhanced Trading Alerts - Улправда
Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksJuly 2025 Snapshot & Fast Gain Stock Trading Tips - Улправда
Taking Stock of Tandem Diabetes Care (TNDM) After t:slim App Launch and Rising Growth Optimism - Sahm
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Book value per share of Tandem Diabetes Care, Inc. – SWB:TD5A - TradingView — Track All Markets
Stock Analysis: Will Tandem Diabetes Care Inc. stock split again soonWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - Улправда
How interest rate cuts could boost Tandem Diabetes Care Inc. stock2025 Breakouts & Breakdowns & Weekly High Return Forecasts - DonanımHaber
What risks investors should watch in Tandem Diabetes Care Inc. stockJuly 2025 Highlights & Reliable Breakout Stock Forecasts - Улправда
Is Tandem Diabetes Care Inc. stock oversold or undervaluedMarket Performance Recap & Community Verified Trade Signals - DonanımHaber
Q3 2025 Healthcare Technology Earnings Review: Revenue Beats & Stock PerformanceNews and Statistics - IndexBox
How resilient is Tandem Diabetes Care Inc. stock in market downturnsJuly 2025 Volume & Real-Time Market Sentiment Alerts - DonanımHaber
Will Tandem Diabetes Care Inc. stock deliver better than expected guidanceWeekly Investment Recap & Community Driven Trade Alerts - ulpravda.ru
Unpacking Q3 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks - Yahoo Finance
What makes Tandem Diabetes Care Inc. (TD5A) stock appealing to growth investorsWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
TNDM Sees Analyst Rating Maintain and Price Target Rise by Truis - GuruFocus
Truist Securities Adjusts Price Target on Tandem Diabetes Care to $24 From $17, Maintains Hold Rating - marketscreener.com
Tandem t:slim Mobile App Now Available in Canada - Business Wire
Bank Watch: Will Tandem Diabetes Care Inc. (TD5A) stock beat value stocksQuarterly Portfolio Summary & Accurate Trade Setup Notifications - Улправда
The Bull Case For Tandem Diabetes Care (TNDM) Could Change Following Mobi-T Pump And App MilestonesLearn Why - Sahm
Mizuho Maintains Tandem Diabetes Care (TNDM) Neutral Recommendation - Nasdaq
Tandem Diabetes (TNDM) EVP reports RSU vesting and updated holdings - Stock Titan
RBC Adjusts Price Target on Tandem Diabetes Care to $30 From $25, Maintains Outperform Rating - marketscreener.com
TNDM: Mizuho Raises Price Target for Tandem Diabetes Care | TNDM Stock News - GuruFocus
Baird upgrades Tandem Diabetes Care stock rating to Outperform on Mobi-T launch - Investing.com Canada
Tandem Diabetes Care Shares Rise After Baird Upgrade - marketscreener.com
Tandem Diabetes (TNDM) Upgraded by Baird Amid MedTech Sector Out - GuruFocus
Tandem upgraded, Zimmer, ResMed downgraded at Baird (TNDM) - Seeking Alpha
Baird Upgrades Tandem Diabetes Care to Outperform From Neutral, Adjusts PT to $30 From $18 - marketscreener.com
TNDM Stock Sees 66.67% Price Target Increase with Outperform Rat - GuruFocus
Baird Upgrades Tandem Diabetes Care (TNDM) - Nasdaq
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - ACCESS Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - TMX Newsfile
Does Tandem Diabetes Care’s Slumping Share Price Signal a New Opportunity in 2025? - Yahoo Finance
Wells Fargo Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
1.64%
0.32%
大文字化:
|
ボリューム (24 時間):